Trial Profile

Study of patient risk factors for febrile neutropenia in NHL receiving (R)CHOP regimen 2

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 26 May 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Filgrastim (Primary) ; Pegfilgrastim (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
Indications Febrile neutropenia
Focus Adverse reactions
Acronyms STOP FN in NHL 2

Most Recent Events

06 Apr 2021 Results analyzing FN incidence, patterns of G CSF preparation and identifying possible predictors of dose reduction and delay of R-CHOP therapy among Japanese patients with B NHL receiving chemotherapy in a real-world setting published in the BMC Cancer
16 Apr 2020 Status changed from active, no longer recruiting to completed.
15 Apr 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com